B1 Vertaisarvioitu muu artikkeli (esim. pääkirjoitus, letter, comment) tieteellisessä lehdessä

Response to Letter Regarding Article, “Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication”

Tekijät: Maaniitty, Teemu; Bär, Sarah; Saraste, Antti

Kustantaja: Ovid Technologies (Wolters Kluwer Health)

Julkaisuvuosi: 2026

Lehti: Circulation: Cardiovascular Imaging

Vuosikerta: 19

Numero: 7

Aloitussivu: 604

Lopetussivu: 605

ISSN: 1941-9651

eISSN: 1942-0080

DOI: https://doi.org/10.1161/CIRCIMAGING.126.019999

Julkaisun avoimuus kirjaamishetkellä: Ei avoimesti saatavilla

Julkaisukanavan avoimuus : Osittain avoin julkaisukanava

Verkko-osoite: https://doi.org/10.1161/circimaging.126.019999

Julkaisussa olevat rahoitustiedot: 
Authors report financial support from the Research Council of Finland, the Finnish Foundation for Cardiovascular Research, Finnish State Research Funding for Turku University Hospital, the University of Turku, Finland, and the Swiss National Science Foundation. Cleerly, Inc performed artificial intelligence-guided quantitative computed tomography (AI-QCT) analysis without costs and provided an unrestricted research grant to the University of Turku. Dr Bär reports research grants to the institution from Medis Medical Imaging Systems, Bangerter-Rhyner Stiftung (Basel, Switzerland) and Abbott, speaker fees from Cleerly, and travel fees from Sanofi, outside the submitted work. Dr Saraste received consultancy fees from Astra Zeneca, Novo Nordisk, and Pfizer, and speaker fees from Abbott, AstraZeneca, BMS, Janssen, and Pfizer, outside the submitted work. The other authors report no conflicts.